Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
367 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,282 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04856761 | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | unknown | — | 160 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05487443 | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | unknown | Phase 2 / Phase 3 | 50 | First People's Hospital of HangzhouOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04362449 | Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration | unknown | Phase 2 | 30 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04637048 | Observational Study on Patients With Hepatobiliary Tumors | unknown | — | 1,000 | Gang Chen, MDOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04401709 | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer | unknown | Phase 3 | 490 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05418543 | CH-EUS in Diagnosis of Inoperable Bile Duct Tumors | unknown | N/A | 40 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05417230 | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | unknown | Phase 2 | 29 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 14, 2022 | clinicaltrials |
| NCT03898895 | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer(CORRECT) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT04608786 | A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer | unknown | Phase 1 | 10 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05056116 | A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer | unknown | N/A | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 27, 2021 | clinicaltrials |
| NCT02232932 | Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma(TRANSPHIL) | unknown | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05064852 | A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma | unknown | — | 200 | Qilu Hospital of Shandong UniversityOTHER | 0 | Oct 1, 2021 | clinicaltrials |
| NCT03603834 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | unknown | Phase 2 | 25 | Khon Kaen UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04337333 | Two-in-one Covered and Uncovered Metal Stent | unknown | N/A | 100 | Ajou University School of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04779788 | I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma | unknown | N/A | 100 | Xuzhou Central HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04961788 | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04961970 | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03951597 | Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04840537 | Cholangioscopy or Conventional Techniques for Indeterminate Biliary Stenosis | unknown | N/A | 150 | Frederic PRAT, MD, PhDOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT04584996 | CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers(CIRCUS) | unknown | — | 186 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Mar 8, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT04731220 | A Questionnaire Survey for Biliary Tract Cancers | unknown | — | 12,000 | Kyungpook National University Chilgok HospitalOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03475966 | Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program | unknown | N/A | 60 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04633382 | ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY | unknown | N/A | 50 | Vitebsk State Medical UniversityOTHER | 0 | Nov 19, 2020 | clinicaltrials |
| NCT03383796 | Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma | unknown | N/A | 30 | Tongji HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2022source: clinicaltrials